Literature DB >> 21088290

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

Vicente E Torres1, Jared J Grantham, Arlene B Chapman, Michal Mrug, Kyongtae T Bae, Bernard F King, Louis H Wetzel, Diego Martin, Mark E Lockhart, William M Bennett, Marva Moxey-Mims, Kaleab Z Abebe, Yan Lin, James E Bost.   

Abstract

BACKGROUND AND OBJECTIVES: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was created to identify markers of disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Linear mixed models were utilized to model effects of baseline parameters on changes in natural-log (ln)-transformed total kidney volume (TKV) and iothalamate clearance (GFR) across time in CRISP participants (creatinine clearance at entry >70 ml/min). Stepwise selection was used to obtain a final main effect model.
RESULTS: TKV increased from year to year, whereas GFR uncorrected for body surface area (BSA) decreased only at year 6. Higher lnTKV and urine sodium excretion (U(Na)V), lower serum HDL-cholesterol, and younger age at baseline associated with greater lnTKV growth from baseline to year 3 and to year 6. Higher lnTKV at baseline associated with greater GFR decline from year 1 to year 3 and to year 6. Higher BSA and 24-hour urine osmolality at baseline associated with greater GFR decline from year 1 to year 6. Higher U(Na)V and lower serum HDL-cholesterol at baseline associated with greater GFR decline from year 1 to year 6 by univariate analysis only. Associations seen during year 1 to year 6 (not seen during year 1 to year 3) reflect the time lag between structural and functional disease progression.
CONCLUSIONS: Serum HDL-cholesterol, U(Na)V, and 24-hour urine osmolality likely affect ADPKD progression. To what extent their modification may influence the clinical course of ADPKD remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088290      PMCID: PMC3082424          DOI: 10.2215/CJN.03250410

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  33 in total

Review 1.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

Review 2.  Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I.

Authors:  Fumikazu Okajima; Koichi Sato; Takao Kimura
Journal:  Endocr J       Date:  2008-08-28       Impact factor: 2.349

Review 3.  Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects.

Authors:  L Bankir
Journal:  Cardiovasc Res       Date:  2001-08-15       Impact factor: 10.787

4.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

Review 5.  A case for water in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Lise Bankir; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 8.237

6.  Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Authors:  Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Kyongtae T Bae; Deborah A Baumgarten; Philip J Kenney; Bernard F King; James F Glockner; Louis H Wetzel; Marijn E Brummer; W Charles O'Neill; Michelle L Robbin; William M Bennett; Saulo Klahr; Gladys H Hirschman; Paul L Kimmel; Paul A Thompson; J Philip Miller
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

7.  Identification of apolipoproteinA1 reduction in the polycystic kidney by proteomics analysis of the Mxi1-deficient mouse.

Authors:  Kyung Hyun Yoo; Yo Na Kim; Min Joo Lee; Je Kyung Seong; Jong Hoon Park
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

8.  Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.

Authors:  Bernard F King; Vicente E Torres; Marijn E Brummer; Arlene B Chapman; Kyongtae T Bae; James F Glockner; Kraisthith Arya; Joel P Felmlee; Jared J Grantham; Lisa M Guay-Woodford; William M Bennett; Saulo Klahr; Gladys H Hirschman; Paul L Kimmel; Paul A Thompson; J Phillip Miller
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

Review 9.  A comprehensive review on salt and health and current experience of worldwide salt reduction programmes.

Authors:  F J He; G A MacGregor
Journal:  J Hum Hypertens       Date:  2008-12-25       Impact factor: 3.012

Review 10.  Vascular consequences of dietary salt intake.

Authors:  Paul W Sanders
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-01
View more
  55 in total

Review 1.  The Treatment of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Wolfgang E Kühn; Gerd Walz
Journal:  Dtsch Arztebl Int       Date:  2015-12-21       Impact factor: 5.594

Review 2.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

3.  Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Salim S Hayek; Douglas P Landsittel; Changli Wei; Martin Zeier; Alan S L Yu; Vicente E Torres; Sharin Roth; Christina S Pao; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2019-06-06       Impact factor: 10.121

Review 4.  An approach to cystic kidney diseases: the clinician's view.

Authors:  Christine E Kurschat; Roman-Ulrich Müller; Mareike Franke; David Maintz; Bernhard Schermer; Thomas Benzing
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

Review 5.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

6.  Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients.

Authors:  Ramanathan Gnanasambandan; Ramprasad Elumalai; Periyasamy Soundararajan; Bhaskar V K S Lakkakula
Journal:  Clin Exp Nephrol       Date:  2015-10-19       Impact factor: 2.801

7.  Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier; Godela M Fick-Brosnahan
Journal:  Nephrol Dial Transplant       Date:  2012-12-04       Impact factor: 5.992

8.  A young patient with a family history of hypertension.

Authors:  Aldo J Peixoto
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

9.  Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.

Authors:  Ladan Zand; Vicente E Torres; Timothy S Larson; Bernard F King; Sanjeev Sethi; Eric J Bergstralh; Andrea Angioi; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2015-11-27       Impact factor: 5.992

Review 10.  New treatments for autosomal dominant polycystic kidney disease.

Authors:  Ming-Yang Chang; Albert C M Ong
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.